Mefford Ivan N, Wade Ekpedeme U
Fort Bend Premier Care, 1505 Liberty Street, Richmond, TX 77469, USA.
Med Hypotheses. 2009 Jul;73(1):29-32. doi: 10.1016/j.mehy.2009.02.010. Epub 2009 Mar 21.
Recent reports have hypothesized a role for exogenously administered gastrin in regulating beta cell function or activity. We surmised that a class of agents, proton pump inhibitors (omeprazole, esomeprazole, pantoprazole, rabeprazole, lansoprazole), known to increase serum gastrin levels could have such an effect, and that data might be available in our database which could address such an effect. We examined our electronic database to obtain glycohemoglobin (HgbA1c) levels measured in the past two years from all type II diabetics and extracted from those diabetics who were concurrently taking a proton pump inhibitor. A comparison of these groups showed an average HgbA1c of 7.6% for type II diabetics not taking a proton pump inhibitor (n=282) and an average HgbA1c of 7.0% for type II diabetics concurrently taking a proton pump inhibitor (n=65), T=-3.61, p=0.002. These data support the hypothesis that proton pump inhibitors can be used to treat type II diabetes.
最近的报告推测，外源性给予胃泌素在调节β细胞功能或活性方面具有一定作用。我们推测，一类已知可提高血清胃泌素水平的药物，即质子泵抑制剂（奥美拉唑、埃索美拉唑、泮托拉唑、雷贝拉唑、兰索拉唑）可能具有这样的效果，并且我们的数据库中可能有相关数据可以证实这种效果。我们查阅了电子数据库，获取过去两年中所有II型糖尿病患者的糖化血红蛋白（HgbA1c）水平，并从同时服用质子泵抑制剂的糖尿病患者中提取数据。对这些组别的比较显示，未服用质子泵抑制剂的II型糖尿病患者（n = 282）的平均糖化血红蛋白水平为7.6%，而同时服用质子泵抑制剂的II型糖尿病患者（n = 65）的平均糖化血红蛋白水平为7.0%，T = -3.61，p = 0.002。这些数据支持了质子泵抑制剂可用于治疗II型糖尿病这一假说。
